Premium
Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer
Author(s) -
Koumakpayi Ismaël H.,
Diallo JeanSimon,
Le Page Cécile,
Lessard Laurent,
FilaliMouhim Abdelali,
Bégin Louis R.,
MesMasson AnneMarie,
Saad Fred
Publication year - 2007
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2007.06992.x
Subject(s) - biochemical recurrence , prostate cancer , proportional hazards model , medicine , breakpoint cluster region , oncology , prostatectomy , urology , univariate analysis , cancer , multivariate analysis , receptor
OBJECTIVE To further evaluate the association between the cytoplasmic or nuclear localization of ErbB3 with biochemical recurrence (BCR) in patients with prostate cancer and positive surgical margins, as there is a greater risk of BCR for such patients after radical prostatectomy (RP). PATIENTS AND METHODS We recently noted that ErbB3, which is normally associated with the plasma membrane, can translocate to the nucleus, an event which appears to be associated with disease progression. We evaluated ErbB3 expression and localization using immunohistochemistry on tissue samples from 55 patients with positive surgical margins after RP; 30 of these 55 (55%) had BCR after 3 years of follow‐up. The relationship between ErbB3 nuclear localization and BCR (prostate‐specific antigen, PSA, >0.3 ng/mL) after RP was analysed by Kaplan‐Meier survival analysis and Cox regression models. RESULTS The BCR‐free survival probability at 3 years was 0.65 and 0.35 for positive and negative nuclear ErbB3, respectively (Kaplan‐Meier, P = 0.029). Patients negative for nuclear ErbB3 had a 2.47‐fold increase in BCR frequency in a univariate Cox model ( P = 0.008) and it remained an independent prognostic marker when combined with clinical prognostic variables in a multivariate model ( P = 0.023). CONCLUSION Low nuclear localization of ErbB3 is a predictor of BCR in patients with prostate cancer and positive surgical margins after RP.